Business Context and Reporting Period
This Form 8-K Current Report was filed by Frequency Therapeutics, Inc. (not Korro Bio, Inc.) on December 1, 2020. The filing reports the appointment of a new Chief Financial Officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figures disclosed relate to executive compensation:
- Sign-on Bonus: $70,000 (one-time).
- Annual Base Salary: $450,000.
- Target Annual Bonus: Up to 40% of base salary.
- Equity Grant: Option to purchase 230,000 shares of common stock.
Material Changes
The primary material change reported is the appointment of Peter P. Pfreundschuh as Chief Financial Officer, effective December 1, 2020. He assumed the responsibilities of principal financial officer and principal accounting officer from Richard Mitrano, the former Vice President of Finance and Operations.
Outlook, Risks, and Unusual Items
Management Commentary: The filing details Mr. Pfreundschuh's extensive background in the pharmaceutical industry, including prior CFO roles at UroGen Pharma, Sucampo Pharmaceuticals, and Immunomedics Inc.
Compensatory Arrangements: The Employment Agreement includes specific severance provisions:
- Termination without cause/Good reason: 12 months of base salary, target annual incentive, and COBRA contributions.
- Change in Control: If termination occurs within 12 months of a change in control, the executive receives 12 months of base salary plus target incentive, 100% acceleration of equity awards, and COBRA contributions.
Risks/Contingencies: No specific business risks or contingencies are disclosed in this filing beyond standard employment agreement terms.
Investor Verification Checklist
- Verify the exact terms of the Employment Agreement (Exhibit 10.1) regarding vesting schedules for the 230,000 stock options.
- Confirm the transition timeline for Richard Mitrano's departure from his previous role.
- Review the press release (Exhibit 99.1) for any additional strategic context regarding the leadership change.
- Note that this filing contains no operational or financial performance updates for the period.